|
|
Volumn 3, Issue 5, 2007, Pages 235-
|
|
What new drugs can nephrologists look forward to in the next year or two?
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALISKIREN;
AMLODIPINE BESYLATE PLUS VALSARTAN;
ANGIOTENSIN RECEPTOR ANTAGONIST;
BELATACEPT;
CONIVAPTAN;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
ERYTHROPOIETIN RECEPTOR;
FERUMOXYTOL;
HEMOGLOBIN;
IMMUNOSUPPRESSIVE AGENT;
MIRCERA;
NANOPARTICLE;
RECOMBINANT ERYTHROPOIETIN;
TOLVAPTAN;
UNCLASSIFIED DRUG;
ANEMIA;
BLOOD PRESSURE REGULATION;
CHRONIC KIDNEY DISEASE;
CLINICAL TRIAL;
DIALYSIS;
DRUG RESEARCH;
EDITORIAL;
FOOD AND DRUG ADMINISTRATION;
FUNDING;
HUMAN;
HYPONATREMIA;
KIDNEY DONOR;
KIDNEY TRANSPLANTATION;
NEPHROLOGIST;
NEPHROLOGY;
PATIENT COMPLIANCE;
PRIORITY JOURNAL;
RENOVASCULAR HYPERTENSION;
SINGLE DRUG DOSE;
AMIDES;
ANEMIA;
ANTIHYPERTENSIVE AGENTS;
BENZAZEPINES;
DRUG ADMINISTRATION SCHEDULE;
DRUG APPROVAL;
DRUG COMBINATIONS;
DRUG DELIVERY SYSTEMS;
ERYTHROPOIETIN;
FERROSOFERRIC OXIDE;
FUMARATES;
HUMANS;
HYPONATREMIA;
IMMUNOSUPPRESSIVE AGENTS;
KIDNEY DISEASES;
NANOPARTICLES;
NEPHROLOGY;
RENAL DIALYSIS;
RENIN;
TACROLIMUS;
|
|
EID: 34247568331
PISSN: 17458323
EISSN: 17458331
Source Type: Journal
DOI: 10.1038/ncpneph0475 Document Type: Editorial |
|
Times cited : (3)
|
|
References (0)
|